Skye Bioscience, Inc. (SKYE)

Nasdaq: SKYE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2011

Grade4.2

◀ Past 3.3● Present 4.0▶ Future 4.8

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Report filed	Mar 10, 2026	Mar 20, 2025	Mar 22, 2024	Mar 31, 2023	Mar 28, 2022	Mar 2, 2021	Mar 23, 2020	Mar 14, 2019	Mar 19, 2018	Mar 10, 2017
Research and development	42,361,879	18,701,694	5,819,461	6,011,805	2,931,437	1,944,411	2,237,956	329,966	311,302	939,040
General and administrative	15,801,686	17,725,741	7,852,340	6,094,617	4,916,277	4,344,602	4,394,622	4,362,557	3,547,927	3,531,540
Total operating expenses	58,163,565	30,192,718	34,735,173	18,311,732	7,847,714	6,289,013	6,632,578	4,692,523	3,859,229	4,470,580
Operating income	-58,163,565	-30,192,718	-34,735,173	-18,311,732	-7,847,714	-6,289,013	-6,632,578	-4,692,523	-3,859,229	-4,470,580
Interest expense	0	749,308	906,270	665,133	769,159	706,385	1,000,713	94,763	667	·
Interest and investment income	1,883,903	3,028,762	99,974	19,011	3	29	26	84	·	·
Other income (expense), net	-502	-2,200	3	·	·	·	·	·	·	·
Total non-operating income (expense)	2,244,151	3,635,666	-2,906,011	-1,163,129	-672,368	-270,086	7,686,003	-14,500,071	·	·
Income before income taxes	-55,919,414	-26,557,052	-37,641,184	-19,474,861	-8,520,082	-6,559,099	1,053,425	-19,192,594	-3,092,698	-3,176,493
Income tax expense	5,400	10,071	3,600	6,741	2,100	1,600	1,600	1,642	1,600	1,600
Net income	-55,924,814	-26,567,123	-37,644,784	-19,481,602	-8,522,182	-6,560,699	1,051,825	-19,194,236	-3,094,298	-3,178,093
Net income to common shareholders	-55,924,814	-26,567,123	-37,644,784	-19,481,602	-8,522,182	-6,560,699	1,051,825	-19,194,236	-4,138,298	-3,503,093
Earnings per share, basic	-1.41	-0.73	-5.37	-8.77^r	-5.00^b	-7.50^b	2.50^b	-40.00^b	-27.50^b	-42.50^b
Earnings per share, diluted	-1.41	-0.73	-5.37	-8.77^r	-5.00^b	-7.50^b	-12.50^b	-40.00^b	-27.50^b	-42.50^b
Earnings per share, basic and diluted	·	·	·	·	·	·	·	-40.00^b	-27.50^b	-42.50^b
Weighted average shares, basic	39,662,664	36,486,519	7,006,038	2,221,080^r	1,626,398^b	922,988^b	540,620^b	484,617^b	111,624^b	75,790^b
Weighted average shares, diluted	39,662,664	36,486,519	7,006,038	2,221,080^r	1,626,398^b	925,684^b	678,241^b	484,617^b	111,624^b	75,790^b
Weighted average shares, basic and diluted	·	·	·	·	·	·	·	484,617^b	111,624^b	75,790^b

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-250 reverse split of Sep 2023.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Research and development spent on inventing what it sells next

us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpense

General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense

Total operating expenses the running costs togetherus-gaap:OperatingExpenses

Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss

Interest expense what its borrowing cost

us-gaap:InterestExpense
us-gaap:InterestExpenseNonoperating

Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest

Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense

Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense

Income before income taxes profit before tax

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit

Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss

Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic

Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted

Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted

Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic

Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

SI Assistanton SKYE · research, not advice